Mycenax Business Summary

Mycenax Biotech Inc. operates as a pure-play biologics Contract Development and Manufacturing Organization (CDMO), generating revenue through end-to-end service fees for cell line development, process optimization, and GMP manufacturing. The company’s business model follows a "Large D, Medium M" strategy, prioritizing high-value development services alongside flexible manufacturing scales for mammalian and microbial-derived biologics. Primary segments include traditional protein therapeutics and high-growth modalities such as Antibody-Drug Conjugates (ADCs) and allogeneic cell therapies, supported by its proprietary "Big-CHO" platform and the recently operational GMP Plant 2 in Zhunan. Mycenax competes directly with regional peers EirGenix, United BioPharma, and Eden Biologics, positioning itself as a specialized, quality-centric partner for the Japanese and Western markets rather than a high-volume commodity manufacturer. The leadership team is led by Dr. Pei-Jiun Chen, who serves as Chairman and CEO following the 2019 merger with TPG Biologics, bringing over two decades of expertise in cell line development and international business expansion. Key technical operations are overseen by Dr. Wei-I Chou, Head of Pharmaceutical Development, and Chih-Yung Lin, VP of the GMP Operation Center, both of whom possess extensive backgrounds in CMC and regulatory compliance. The company is strategically anchored by its largest shareholder, Center Laboratories Inc., and benefits from the legacy of Director and Honorary President Lin Jung-Chin, a prominent figure in the Taiwanese biotech industry. This institutional backing, combined with significant investment from Japanese partners, provides Mycenax with the financial stability and cross-border networks required to scale its international CDMO footprint.